By Payer Type

Medicare Advantage / Part D Market Analysis

Cross-industry research covering Medicare Advantage / Part D across 1 market reportspanning Pharmaceuticals & Life Sciences – Molecular Diagnostics / Consumer Genomics.

1 Reports
1 Industries

Reports Covering Medicare Advantage / Part D

Direct to Consumer Genetic Sequencing Market to Reach USD 4.7 Billion by 2033 at 7.2% CAGR

Pharmaceuticals & Life Sciences – Molecular Diagnostics / Consumer Genomics·Market: USD 2.7 Billion (2025)·CAGR: 7.2%

Medicare Advantage plans have broader supplemental benefit flexibility than traditional FFS Medicare, and several MA plans have added pharmacogenomic screening to their supplemental benefit packages starting in 2024. Our base case projects MA genomic coverage expanding materially post-2026 (Claritas model).

6%

Market Share

12.1%

Segment CAGR

Explore More Segments

Browse all market segments across our research coverage.

View all segments